Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents

Ammar, Usama M.; Abdel-Maksoud, Mohammed S.; Oh, Chang-Hyun

Abstract

Frequent oncogenic mutations have been identified in MAPK (mitogen-activated protein kinase) signaling pathway components. As a result, MAPK pathway is associated with human cancer initiation, in particular RAF (rapidly accelerated fibrosarcoma) component. The mutation in RAF component leads to auto-activation of MAPK signaling pathway, stimulating the uncontrolled cell growth and proliferation. In last few years, diverse chemical scaffolds have been identified as RAF inhibitors. Most of these scaffolds show potent anti-cancer activity. The present review highlights the recent investigations of RAF inhibitors during the last five years.

Citation

Ammar, U. M., Abdel-Maksoud, M. S., & Oh, C.-H. (2018). Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry, 158, 144-166. https://doi.org/10.1016/j.ejmech.2018.09.005

• Journal Article Type: Review
• Acceptance Date: Sep 3, 2018
• Online Publication Date: Sep 6, 2018
• Publication Date: 2018-10
• Deposit Date: Dec 11, 2022
• Journal: European Journal of Medicinal Chemistry
• Print ISSN: 0223-5234
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 158
• Pages: 144-166
• DOI: https://doi.org/10.1016/j.ejmech.2018.09.005
• Keywords: MAPK, RAF inhibitors, Anti-cancer agents
• Public URL: http://researchrepository.napier.ac.uk/Output/2982083